Biopharmaceutical company is partnering with Sysmex Inostics to identify appropriate study candidates with the OncoBEAM™ ESR1 liquid biopsy test COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical...
Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that...
Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare Epilepsies; Initial Data from Phase 2 ARCADE Trial...
Global professional services firm ZS has launched Clinical Design Center, an integrated technology platform and services solution that allows cross-functional teams within pharmaceutical organizations to collaborate in a virtual environment to make better data-driven...
As technology has altered the way we communicate with each other, it is no secret that the written word has lost leverage in the eyes of content consumers. That is why video content, specifically live video, has superseded blog and written content in driving...
Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies suggest that Akt-driven CaP cells are genetically susceptible to mammalian target of rapamycin (mTOR,...
Email
Text